Goldline Pharmaceutical reported a 45% year-on-year increase in net profit for FY26, reaching ₹411.71 lakhs. The Nagpur-based pharma firm also saw its revenue from operations and other income rise by 11% to ₹3,119.88 lakhs during the period.

The results were presented to shareholders at the company’s 22nd Annual General Meeting held on August 29, 2026, in Nagpur. This marks the first AGM since Goldline Pharmaceutical listed its equity shares on the BSE SME Platform in May 2026.

Financial Performance

Whole-Time Director Swapan Khandelwal outlined the financial highlights for the fiscal year ended March 31, 2026. The company’s Profit Before Tax (PBT) grew significantly from ₹385.84 lakhs in FY25 to ₹538.54 lakhs in FY26.

The Earnings Per Share (EPS) improved from ₹4.11 to ₹5.97, reflecting the stronger bottom-line performance.

What the Numbers Show

The divergence between revenue growth and profit expansion indicates improved operational efficiency or cost management. While top-line revenue increased by approximately 11%, pre-tax profits surged nearly 40%. This suggests that gross margins expanded or operating expenses were controlled effectively relative to sales growth, allowing a larger portion of incremental revenue to flow through to the bottom line.

Governance and Dividends

Shareholders approved several key resolutions, including the adoption of standalone audited financial statements and the re-appointment of Executive Director Prashant Karkare. The Board also declared a dividend of ₹12 per preference share of face value ₹100 each for FY26.

Special business items included approvals for material related-party transactions with Activista Healthcare Private Limited, Nucleage Pharma Solutions Private Limited, and Numerius Healthcare Private Limited. Additionally, members approved the borrowing of unsecured loans from directors, with an option for conversion into equity shares.

Future Outlook

Executive Director Prashant Karkare highlighted the company’s focus on strengthening its product portfolio and expanding geographical presence. Management plans to explore opportunities in specialty and super-specialty segments while enhancing engagement with the medical fraternity.

Chairman & Managing Director Amol Mujumdar emphasized that the recent listing has strengthened the financial foundation and enhanced capital market visibility. The company remains committed to sustainable value creation through disciplined execution and regulatory compliance.

Swapan Khandelwal, promoter and whole-time director of Goldline Pharmaceutical Limited , acquired 78,000 equity shares through an open market purchase on August 28, 2026.

The acquisition increases his total holding to 2,887,988 shares, representing 30.08% of the company’s total paid-up share capital. This marks a rise from his previous stake of 29.27% (2,809,988 shares).

Shareholding Details

The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing confirms that none of the acquired shares are encumbered by pledges or liens.

The company’s total equity share capital remains unchanged at 9,600,000 equity shares following the trade. There were no acquisitions or sales of warrants, convertible securities, or other instruments entitling the acquirer to voting rights during this period.

What the Numbers Show

The open market purchase indicates a consolidation of promoter interest without altering the company’s diluted share capital structure. With zero encumbrances reported both before and after the transaction, the promoter’s holding remains unpledged.